Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06952504RecruitingPhase 3
Comparing two drug combos for advanced endometrial cancer
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
Mobile, AlabamaAges 18 years+ - NCT06952010RecruitingPhase 1
Study of XB628 alone and with zanzalintinib for advanced solid tumors
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06941090Recruiting
Stool sample collection for nutrition gut health study
This study asks participants of the NutriNet-Santé health study to provide a stool sample. Researchers want to understand how diet and gut bacteria affect health.
BobignyAges 18 years+ - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Dothan, AlabamaAges 18–70 - NCT06938269RecruitingPhase 1
Study of MWN109 tablets in healthy adults
This trial tests a new tablet called MWN109 in healthy adults to see how safe it is and how the body handles it. It has two parts: one for people with a wide range of body weights, and another specifically for people with higher body weight. The results will help guide future studies.
Adelaide, South AustraliaAges 18–60 - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Dothan, AlabamaAges 18–70 - NCT06936735RecruitingPhase 1
HS-20108 for advanced solid tumors (phase 1)
This phase 1 study tests an investigational drug called HS-20108 in people with advanced solid tumors. It aims to find a safe dose and see how well the drug works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Los Angeles, CaliforniaAges 1 month–17 years - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT06923163Recruiting
How exercise affects your body's metabolism
This study looks at how exercise changes your metabolism in people who are not very active. It may help you understand how physical activity can benefit your health.
Shenzhen, GuangdongAges 18–40 - NCT06926075RecruitingPhase 1/Phase 2
Early trial of KESONOTIDE™ for solid tumors
This trial tests a new tablet called KESONOTIDE™ for people with solid tumors that have spread. The goal is to see if it can help when other treatments have stopped working or are not an option.
Kogarah, New South WalesAges 18 years+ - NCT06926621Enrolling by invitationPhase 2
Long-term safety and effectiveness of VX-670 for myotonic dystrophy
This study is for people who already received VX-670 in a previous trial and want to continue treatment. It will check the drug's long-term safety and how well it works for myotonic dystrophy type 1.
St Louis, MissouriAges 18 years+ - NCT06925685Enrolling by invitation
Long-term follow-up after CAR T-cell therapy
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
Buffalo, New YorkAges Any age - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06926920RecruitingPhase 1/Phase 2
Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06930625RecruitingPhase 3
Study of Debio 4126 for acromegaly patients on current therapy
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
Los Angeles, CaliforniaAges 18 years+ - NCT06920628RecruitingPhase 1
Brain scan study for long COVID neurological symptoms
This study uses a special PET scan to look at brain inflammation in people with neurological symptoms after COVID-19. It aims to understand how inflammation might be linked to ongoing problems like brain fog or memory issues.
Bethesda, MarylandAges 18–70 - NCT06914128RecruitingPhase 1/Phase 2
Study of a PRMT5 inhibitor for MTAP-deleted solid tumors
This trial tests a new drug called BAY 3713372 in people with solid tumors that have a specific genetic change called MTAP deletion. The drug targets a process inside cells that may help stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT06914908Enrolling by invitationPhase 2
Long-term safety study of lunsekimig for nasal polyps
This study tests the long-term safety and effectiveness of a medication called lunsekimig for people with chronic sinusitis and nasal polyps. It is for those who already completed a previous study on this drug.
La Jolla, CaliforniaAges 18 years+ - NCT06916507Recruiting
Early treatment with a new Parkinson's drug
This study tests a new form of Parkinson's medication given through a pump to see how well it works in everyday life for people in the early stages of advanced Parkinson's. It may help control symptoms and improve daily function.
Allensbach, Baden-WurttembergAges 18–67 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06135350RecruitingPhase 2
Preventing infections in ICU patients on ventilators
This trial tests an experimental drug called Fluorothiazinone to prevent serious bacterial infections in ICU patients who are on a breathing machine (ventilator) or likely to need one soon. It includes patients with COVID-19 pneumonia, stroke, or heart failure.
Moscow, MoscowAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,290 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.